Myriad Genetics Net Worth
Myriad Genetics Net Worth Breakdown | MYGN |
Myriad Genetics Net Worth Analysis
Myriad Genetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Myriad Genetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Myriad Genetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Myriad Genetics' net worth analysis. One common approach is to calculate Myriad Genetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Myriad Genetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Myriad Genetics' net worth. This approach calculates the present value of Myriad Genetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Myriad Genetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Myriad Genetics' net worth. This involves comparing Myriad Genetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Myriad Genetics' net worth relative to its peers.
Enterprise Value |
|
To determine if Myriad Genetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Myriad Genetics' net worth research are outlined below:
| Myriad Genetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 753.2 M. Net Loss for the year was (263.3 M) with profit before overhead, payroll, taxes, and interest of 569.5 M. | |
| Myriad Genetics currently holds about 205.1 M in cash with (110.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.54. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: The Goldman Sachs Group Cuts Myriad Genetics Price Target to 18.00 - MarketBeat |
Myriad Genetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Myriad Genetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Myriad Genetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Myriad Genetics Target Price Consensus
Myriad target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Myriad Genetics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 15 | Buy |
Most Myriad analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Myriad stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Myriad Genetics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMyriad Genetics Target Price Projection
Myriad Genetics' current and average target prices are 12.91 and 21.20, respectively. The current price of Myriad Genetics is the price at which Myriad Genetics is currently trading. On the other hand, Myriad Genetics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Myriad Genetics Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Myriad Genetics Target Price
Know Myriad Genetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Myriad Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Myriad Genetics backward and forwards among themselves. Myriad Genetics' institutional investor refers to the entity that pools money to purchase Myriad Genetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sei Investments Co | 2024-09-30 | 2.4 M | Loomis, Sayles & Company Lp | 2024-09-30 | 2.2 M | Geode Capital Management, Llc | 2024-09-30 | 2.2 M | Nuveen Asset Management, Llc | 2024-09-30 | 1.4 M | Glenview Capital Management Llc | 2024-09-30 | 1.3 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 967.2 K | Blackrock Inc | 2024-09-30 | 15.4 M | Vanguard Group Inc | 2024-09-30 | 10.3 M |
Follow Myriad Genetics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.14 B.Market Cap |
|
Project Myriad Genetics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.44) | |
| Return On Capital Employed | (0.23) | (0.22) | |
| Return On Assets | (0.21) | (0.20) | |
| Return On Equity | (0.30) | (0.29) |
When accessing Myriad Genetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Myriad Genetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Myriad Genetics' profitability and make more informed investment decisions.
Evaluate Myriad Genetics' management efficiency
Myriad Genetics has return on total asset (ROA) of (0.0535) % which means that it has lost $0.0535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.164) %, meaning that it created substantial loss on money invested by shareholders. Myriad Genetics' management efficiency ratios could be used to measure how well Myriad Genetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of January 2025, Return On Tangible Assets is likely to grow to -0.44. In addition to that, Return On Capital Employed is likely to grow to -0.22. At this time, Myriad Genetics' Non Current Assets Total are very stable compared to the past year. As of the 30th of January 2025, Non Currrent Assets Other is likely to grow to about 14.6 M, while Total Assets are likely to drop about 670.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.51 | 5.46 | |
| Tangible Book Value Per Share | 2.03 | 3.44 | |
| Enterprise Value Over EBITDA | (7.76) | (8.15) | |
| Price Book Value Ratio | 2.33 | 4.16 | |
| Enterprise Value Multiple | (7.76) | (8.15) | |
| Price Fair Value | 2.33 | 4.16 | |
| Enterprise Value | 1.1 B | 790.3 M |
At Myriad Genetics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 1.4385 | Revenue | Quarterly Revenue Growth 0.112 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Myriad Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Myriad Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Myriad Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Myriad Genetics Corporate Filings
8K | 15th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Myriad Genetics Earnings Estimation Breakdown
The calculation of Myriad Genetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Myriad Genetics is estimated to be 0.034 with the future projection ranging from a low of 0.0325 to a high of 0.0375. Please be aware that this consensus of annual earnings estimates for Myriad Genetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.03 Lowest | Expected EPS | 0.04 Highest |
Myriad Genetics Earnings Projection Consensus
Suppose the current estimates of Myriad Genetics' value are higher than the current market price of the Myriad Genetics stock. In this case, investors may conclude that Myriad Genetics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Myriad Genetics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 16 | 33.54% | 0.06 | 0.034 | -1.28 |
Myriad Genetics Earnings History
Earnings estimate consensus by Myriad Genetics analysts from Wall Street is used by the market to judge Myriad Genetics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Myriad Genetics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Myriad Genetics Quarterly Gross Profit |
|
Myriad Genetics Earnings per Share Projection vs Actual
Actual Earning per Share of Myriad Genetics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Myriad Genetics predict the company's earnings will be in the future. The higher the earnings per share of Myriad Genetics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Myriad Genetics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Myriad Genetics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Myriad Genetics should always be considered in relation to other companies to make a more educated investment decision.Myriad Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Myriad Genetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | 0.02 | 0.06 | 0.04 | 200 | ||
2024-08-06 | 2024-06-30 | -0.01 | 0.05 | 0.06 | 600 | ||
2024-05-07 | 2024-03-31 | -0.1 | -0.01 | 0.09 | 90 | ||
2024-02-27 | 2023-12-31 | 0.01 | 0.04 | 0.03 | 300 | ||
2023-11-06 | 2023-09-30 | -0.08 | -0.03 | 0.05 | 62 | ||
2023-08-03 | 2023-06-30 | -0.08 | -0.08 | 0.0 | 0 | ||
2023-05-03 | 2023-03-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2023-02-28 | 2022-12-31 | -0.16 | -0.12 | 0.04 | 25 | ||
2022-11-01 | 2022-09-30 | -0.06 | -0.19 | -0.13 | 216 | ||
2022-08-04 | 2022-06-30 | 0.01 | 0.04 | 0.03 | 300 | ||
2022-05-05 | 2022-03-31 | -0.07 | -0.03 | 0.04 | 57 | ||
2022-02-24 | 2021-12-31 | -0.02 | -0.02 | 0.0 | 0 | ||
2021-11-02 | 2021-09-30 | -0.02 | -0.02 | 0.0 | 0 | ||
2021-08-03 | 2021-06-30 | -0.09 | 0.12 | 0.21 | 233 | ||
2021-05-03 | 2021-03-31 | -0.14 | -0.06 | 0.08 | 57 | ||
2021-02-23 | 2020-12-31 | -0.12 | -0.12 | 0.0 | 0 | ||
2020-11-09 | 2020-09-30 | -0.3 | -0.15 | 0.15 | 50 | ||
2020-08-13 | 2020-06-30 | -0.47 | -0.31 | 0.16 | 34 | ||
2020-05-05 | 2020-03-31 | 0.01 | -0.08 | -0.09 | 900 | ||
2020-02-06 | 2019-12-31 | 0.29 | 0.23 | -0.06 | 20 | ||
2019-11-04 | 2019-09-30 | 0.32 | 0.08 | -0.24 | 75 | ||
2019-08-13 | 2019-06-30 | 0.47 | 0.41 | -0.06 | 12 | ||
2019-05-07 | 2019-03-31 | 0.42 | 0.46 | 0.04 | 9 | ||
2019-02-05 | 2018-12-31 | 0.39 | 0.38 | -0.01 | 2 | ||
2018-11-06 | 2018-09-30 | 0.3 | 0.43 | 0.13 | 43 | ||
2018-08-21 | 2018-06-30 | 0.33 | 0.38 | 0.05 | 15 | ||
2018-05-08 | 2018-03-31 | 0.27 | 0.31 | 0.04 | 14 | ||
2018-02-06 | 2017-12-31 | 0.24 | 0.31 | 0.07 | 29 | ||
2017-11-07 | 2017-09-30 | 0.21 | 0.26 | 0.05 | 23 | ||
2017-08-08 | 2017-06-30 | 0.26 | 0.3 | 0.04 | 15 | ||
2017-05-02 | 2017-03-31 | 0.23 | 0.27 | 0.04 | 17 | ||
2017-02-07 | 2016-12-31 | 0.24 | 0.26 | 0.02 | 8 | ||
2016-11-01 | 2016-09-30 | 0.25 | 0.23 | -0.02 | 8 | ||
2016-08-09 | 2016-06-30 | 0.37 | 0.36 | -0.01 | 2 | ||
2016-05-03 | 2016-03-31 | 0.38 | 0.41 | 0.03 | 7 | ||
2016-02-02 | 2015-12-31 | 0.41 | 0.45 | 0.04 | 9 | ||
2015-11-03 | 2015-09-30 | 0.35 | 0.41 | 0.06 | 17 | ||
2015-08-11 | 2015-06-30 | 0.41 | 0.41 | 0.0 | 0 | ||
2015-05-05 | 2015-03-31 | 0.39 | 0.4 | 0.01 | 2 | ||
2015-02-03 | 2014-12-31 | 0.35 | 0.4 | 0.05 | 14 | ||
2014-11-04 | 2014-09-30 | 0.32 | 0.25 | -0.07 | 21 | ||
2014-08-12 | 2014-06-30 | 0.46 | 0.44 | -0.02 | 4 | ||
2014-05-06 | 2014-03-31 | 0.46 | 0.6 | 0.14 | 30 | ||
2014-02-04 | 2013-12-31 | 0.46 | 0.66 | 0.2 | 43 | ||
2013-11-05 | 2013-09-30 | 0.45 | 0.68 | 0.23 | 51 | ||
2013-08-13 | 2013-06-30 | 0.44 | 0.53 | 0.09 | 20 | ||
2013-05-07 | 2013-03-31 | 0.4 | 0.46 | 0.06 | 15 | ||
2013-02-05 | 2012-12-31 | 0.38 | 0.42 | 0.04 | 10 | ||
2012-11-05 | 2012-09-30 | 0.32 | 0.36 | 0.04 | 12 | ||
2012-08-14 | 2012-06-30 | 0.34 | 0.34 | 0.0 | 0 | ||
2012-05-01 | 2012-03-31 | 0.32 | 0.34 | 0.02 | 6 | ||
2012-01-31 | 2011-12-31 | 0.31 | 0.33 | 0.02 | 6 | ||
2011-11-01 | 2011-09-30 | 0.28 | 0.29 | 0.01 | 3 | ||
2011-08-09 | 2011-06-30 | 0.29 | 0.3 | 0.01 | 3 | ||
2011-05-03 | 2011-03-31 | 0.25 | 0.31 | 0.06 | 24 | ||
2011-01-27 | 2010-12-31 | 0.26 | 0.26 | 0.0 | 0 | ||
2010-11-02 | 2010-09-30 | 0.23 | 0.24 | 0.01 | 4 | ||
2010-08-10 | 2010-06-30 | 0.33 | 0.39 | 0.06 | 18 | ||
2010-05-04 | 2010-03-31 | 0.39 | 0.33 | -0.06 | 15 | ||
2010-02-02 | 2009-12-31 | 0.34 | 0.36 | 0.02 | 5 | ||
2009-11-03 | 2009-09-30 | 0.34 | 0.31 | -0.03 | 8 | ||
2009-08-25 | 2009-06-30 | 0.22 | 0.37 | 0.15 | 68 | ||
2009-05-04 | 2009-03-31 | 0.24 | 0.25 | 0.01 | 4 | ||
2009-02-03 | 2008-12-31 | 0.16 | 0.22 | 0.06 | 37 | ||
2008-11-04 | 2008-09-30 | 0.07 | 0.15 | 0.08 | 114 | ||
2008-08-19 | 2008-06-30 | -0.13 | 0.7 | 0.83 | 638 | ||
2008-05-06 | 2008-03-31 | -0.05 | -0.05 | 0.0 | 0 | ||
2008-02-05 | 2007-12-31 | -0.09 | -0.05 | 0.04 | 44 | ||
2007-11-01 | 2007-09-30 | -0.12 | -0.09 | 0.03 | 25 | ||
2007-08-21 | 2007-06-30 | -0.09 | -0.09 | 0.0 | 0 | ||
2007-05-01 | 2007-03-31 | -0.13 | -0.07 | 0.06 | 46 | ||
2007-02-06 | 2006-12-31 | -0.15 | -0.11 | 0.04 | 26 | ||
2006-11-07 | 2006-09-30 | -0.15 | -0.15 | 0.0 | 0 | ||
2006-08-22 | 2006-06-30 | -0.14 | -0.14 | 0.0 | 0 | ||
2006-05-02 | 2006-03-31 | -0.13 | -0.12 | 0.01 | 7 | ||
2006-02-07 | 2005-12-31 | -0.16 | -0.11 | 0.05 | 31 | ||
2005-10-26 | 2005-09-30 | -0.18 | -0.15 | 0.03 | 16 | ||
2005-08-23 | 2005-06-30 | -0.16 | -0.16 | 0.0 | 0 | ||
2005-05-04 | 2005-03-31 | -0.17 | -0.16 | 0.01 | 5 | ||
2005-02-08 | 2004-12-31 | -0.17 | -0.16 | 0.01 | 5 | ||
2004-11-09 | 2004-09-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2004-08-18 | 2004-06-30 | -0.19 | -0.18 | 0.01 | 5 | ||
2004-05-04 | 2004-03-31 | -0.2 | -0.19 | 0.01 | 5 | ||
2004-02-03 | 2003-12-31 | -0.18 | -0.18 | 0.0 | 0 | ||
2003-11-12 | 2003-09-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2003-08-26 | 2003-06-30 | -0.11 | -0.13 | -0.02 | 18 | ||
2003-05-06 | 2003-03-31 | -0.11 | -0.1 | 0.01 | 9 | ||
2003-02-04 | 2002-12-31 | -0.11 | -0.13 | -0.02 | 18 | ||
2002-11-05 | 2002-09-30 | -0.11 | -0.11 | 0.0 | 0 | ||
2002-08-22 | 2002-06-30 | -0.1 | -0.14 | -0.04 | 40 | ||
2002-05-07 | 2002-03-31 | -0.08 | -0.07 | 0.01 | 12 | ||
2002-02-05 | 2001-12-31 | -0.06 | -0.05 | 0.01 | 16 | ||
2001-11-07 | 2001-09-30 | -0.06 | -0.02 | 0.04 | 66 | ||
2001-08-21 | 2001-06-30 | -0.05 | -0.04 | 0.01 | 20 | ||
2001-05-09 | 2001-03-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2001-02-06 | 2000-12-31 | -0.05 | -0.02 | 0.03 | 60 | ||
2000-11-02 | 2000-09-30 | -0.05 | -0.04 | 0.01 | 20 | ||
2000-08-22 | 2000-06-30 | -0.06 | -0.06 | 0.0 | 0 | ||
2000-05-09 | 2000-03-31 | -0.06 | -0.05 | 0.01 | 16 | ||
2000-02-10 | 1999-12-31 | -0.06 | -0.05 | 0.01 | 16 | ||
1999-11-11 | 1999-09-30 | -0.06 | -0.06 | 0.0 | 0 | ||
1999-08-31 | 1999-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
1999-05-12 | 1999-03-31 | -0.04 | -0.06 | -0.02 | 50 | ||
1998-11-11 | 1998-09-30 | -0.03 | -0.07 | -0.04 | 133 | ||
1998-08-20 | 1998-06-30 | -0.07 | -0.08 | -0.01 | 14 | ||
1998-05-07 | 1998-03-31 | -0.07 | -0.07 | 0.0 | 0 | ||
1998-02-05 | 1997-12-31 | -0.06 | -0.06 | 0.0 | 0 | ||
1997-11-06 | 1997-09-30 | -0.07 | -0.05 | 0.02 | 28 | ||
1997-09-10 | 1997-06-30 | 0 | 0.01 | 0.01 | 0 | ||
1997-05-06 | 1997-03-31 | -0.07 | -0.09 | -0.02 | 28 | ||
1997-02-11 | 1996-12-31 | -0.07 | -0.1 | -0.03 | 42 | ||
1996-11-11 | 1996-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
1996-05-03 | 1996-03-31 | -0.03 | -0.05 | -0.02 | 66 | ||
1996-02-14 | 1995-12-31 | -0.03 | -0.02 | 0.01 | 33 | ||
1995-11-21 | 1995-09-30 | -0.1 | -0.08 | 0.02 | 20 |
Myriad Genetics Corporate Management
| Justin Hunter | Interim Secretary | Profile | |
| Nicole Lambert | Chief Officer | Profile | |
| Jennifer Fox | Chief Officer | Profile | |
| Clivetty Martinez | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 0.112 | Return On Assets | Return On Equity |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.